ERp29 was found in the retina of DKO mice. Conclusion: A broad spectrum of AMD pathologies with early onset and high penetrance in these mice implicate certain chemokines, A2E and endoplasmic reticulum proteins in AMD pathogenesis.
is no known cure for this disease and the treatment options are limited [3] . Therefore, it is critical to study this disease using suitable animal models [4] including genetically engineered animal models. Although mice have no macula, the use of mouse models can still provide basic physiology and pathology relevant to human AMD.
We have reported that a loss-of-function variation within CX3CR1 (T280M/V249I) is associated with AMD in a case-control study. This association was further demonstrated via molecular pathological analyses. CX3CR1 polymorphisms are associated with an increased risk of AMD development [5] . Decreased CX3CR1 expression is detected in AMD eyes, in particular, within the macular region [5, 6] . Interestingly, Cx3cr1 -deficient mice have recently been reported to develop AMD-like features including 'drusen' formation, progressive accumulation of subretinal microglia and photoreceptor degeneration in aged animals [7, 8] .
Senescent Ccl2-or Ccr2 -deficient mice are reported to develop AMD-like pathology including accumulation of lipofuscin in the retinal pigment epithelium (RPE) drusen, photoreceptor atrophy and choroidal neovascularization [9] . Complement and IgG deposits are also found in the RPE and choroid in these mice. Impaired macrophage function may contribute to AMD pathology in this model.
The hypothesis that deficiencies in both Cx3cr1 and Ccl2 might have a synergistic effect resulting in a phenotype displaying typical AMD features with early onset and high penetrance has led us to generate a Ccl2/Cx3cr1 double-knockout (DKO) [10] . This article highlights the pathological features of our DKO mice.
Generation of DKO Mice
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Characterization of DKO Mice
DKO mice appear normal although slightly underweight and smaller in size. They are less fertile, averaging 4 pups per litter as compared to 8 pups in normal C57BL/6 mice. Loss of hair and pigmentation are observed in some DKO. Most importantly, all DKO mice show multiple small retinal lesions [10] . These lesions are similar to human drusen and can be observed as early as at 6 weeks of age. The round or dome-shaped, yellowish deposits are observed mostly within the deep retina subretinal space ( fig. 1 ). Most lesions will become larger and confluent (by 4-6 months) and some progress to flattened or scar-like atrophic areas with aging ( 1 6 months).
The most prominent histopathology noted is the presence of abnormal RPE cells ( fig. 2 ). Focal or diffuse RPE hypopigmentation, depigmentation, vacuolization and atrophy resulting from loss of melanosomes and increased lipofuscin are frequently observed [10] . In some rare cases, focal RPE hyperpigmentation is also observed. An abnormal thickened Bruch membrane further characterized by irregular deposits also develops. In general, these drusen appear to be much smaller as compared to classical drusen in AMD patients. Spontaneous choroidal neovascularization develops in approximately 15% of DKO mice. These choroidal neovascularizations are surrounded by little or no areas of hemorrhage and are often tiny and fragile, thus they are difficult to identify. Photoreceptor abnormalities are usually in small foci of the outer nuclear layer. Photoreceptor atrophy is found in older DKO mice.
DKO mice demonstrate aberrant immunological responses. Complement factor deposits and microglial accumulation are detected surrounding, as well as within, the lesions [10] . These mice show decreased response to lipopolysaccharide as compared to C57BL/6 mice. This may be primarily due to the low expression of toll-like receptor 4 observed in the DKO mice [11] . DKO mice exhibit microglial activation impaired macrophage recruitment and function, which may be associated with the development of the observed AMD-like lesions.
A2E (N-retinylidene-N-retinylethanolamine), a major fluorophore of lipofuscin, is a derivative of retinoid metabolism. Lipofuscin is a product of RPE phagocytosis of photoreceptor outer segments and has been shown to increase and accumulate in the RPE of AMD eyes. A 3-to 4-fold increase in A2E is found within the retina and RPE of DKO as compared to C57BL/6 mice [10] . Using spectral fluorescence microscopy, a higher autofluorescence, originating mainly from A2E, is measured in both young and old DKO as compared to C57BL/6 mice ( fig. 3 a, b) .
The autofluorescence is associated specifically with the RPE and has a spectral emission peak at ϳ 600-615 nm. The emission spectrum is consistent with that of unbleached RPE cell cultures fed A2E when excited at 458 nm. This likely reflects that more A2E and perhaps its precursors are present in the RPE of the DKO and the spectrum is not dominated by oxidized A2E granules, which have an emission maximum typically between 530 and 560 nm when excited at 458 nm [Majumdar and Bonner, unpublished data].
Proteomics of the retina and RPE demonstrate 4 differentially expressed proteins in DKO [10] . One of them is the ERp29 precursor. ERp29 protein is associated with neurodegenerative diseases [12] . ERp29 is a resident endoplasmic reticulum (ER) protein, which functions as a chaperone [13, 14] . Chaperones are proteins that help and guide other proteins as they fold and progress along the productive pathways. Misfolded proteins could aggregate and interfere with intracellular movement. Many chaperones are upregulated under conditions where misfolded proteins accumulate. ERp29 also facilitates the export of membrane or secretory proteins. ERp29 protein is considered to be associated with neurodegenerative diseases [12] . Significantly lower levels of ERp29 (protein and transcript) are found in the eyes, particularly within the retinal lesions, of DKO mice as compared to C57BL/6 mice [10] . This finding supports the reports of decreased ERp29 in the aging retina and AMD maculae [15, 16] . Low ERp29 protein levels may impact chaperone function and lead to the accumulation of incompletely folded aggregates such as lipofuscin or drusen, eventually resulting in the RPE damage observed in DKO mice.
Implications of DKO Mice
Omega-3 fatty acids are long-chain polyunsaturated fatty acids (LCPUFA) that cannot be synthesized de novo by mammals [17] . They have neuroprotective, anti-inflammatory and antiangiogenic effects [18] [19] [20] . One of the major components of omega-3 LCPUFA is docosahexaenoic acid, which activates HSP70, a chaperone protein. Omega-3 LCPUFA is metabolized in the ER and stimulates post-ER presecretory proteolysis [21] . Higher intake of omega-3 LCPUFA and fish is associated with a decreased likelihood of developing AMD [22, 23] .
In a preliminary experiment, DKO mice were fed with either a high or low in omega-3 LCPUFA starting from preconception. Although similar retinal lesions were observed at 6 weeks of age in both groups, the number of lesions was decreased in the mice that ingested a high omega-3 LCPUFA diet ( fig. 4 a, b) . In contrast, in the mice that ingested a diet deprived of omega-3 LCPUFA, the retinal lesions continued to progress ( fig. 4 c, d ). The likely cause for this observation is the enriched docosahexaenoic acid intake in the mice fed with the high omega-3 LCPUFA diet. Docosahexaenoic acid is shown to promote RPE cell survival by being the precursor of neuroprotectin D1. Neuroprotectin D1 inhibits oxidativestress-mediated proinflammatory gene induction and apoptosis [24] . Further investigations on these mice are currently underway in our laboratory.
Conclusion
DKO mice present a board spectrum of clinical, biochemical, immunological and pathological features of human AMD lesions. The spontaneously developing features are highly reproducible. In these mice, the disease onset is earlier than that observed in most genetically engineered AMD mouse models. DKO mice implicate the important roles of certain inflammatory molecules and chaperone proteins in AMD pathogenesis. DKO mice may be used to direct future therapeutic strategies, such as the attenuation of retinal pathology with a diet rich in omega-3 LCPUFA for the treatment of AMD. 
